Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Tenet Healthcare Q1 2026 Earnings Call - Outperformance Amid Exchange Headwinds and Aggressive ASC M&A
Tenet Healthcare delivered a resilient start to 2026, reporting Q1 adjusted EBITDA of $1.16 billion and beating management's own expectations despite a shifting payer landscape. The company navigated ...
- Tenet Healthcare reported Q1 2026 net operating revenues of $5.4 billion and consolidated adjusted EBITDA of $1.162 billion, representing a 21.6% adjusted EBITDA margin and beating management's internal expectations.
- Hospital segment adjusted EBITDA reached $678 million with a 16.7% margin, driven by disciplined expense management, AI-driven efficiencies, and successful execution of a high-acuity strategy that offset a 10% decline in exchange admissions.
- USPI generated $484 million in adjusted EBITDA (36.7% margin), with same-facility revenues growing 5.3% and double-digit volume growth in total joint replacements, highlighting strong demand for outpatient surgical services.
- +9 more takeaways
Tyler Technologies Q1 2026 Earnings Call - Cloud Momentum and AI Trust Drive Record Revenue and Raised Guidance
Tyler Technologies delivered a record-setting first quarter in 2026, driven by accelerating cloud adoption, robust public sector demand, and strategic acquisitions. Recurring revenue and total revenue...
- Total and recurring revenue reached new record highs in Q1 2026, reflecting strong demand across public sector software and cloud services.
- Free cash flow more than doubled year-over-year, driven by working capital improvements, strong AR collections, and lower capital expenditures.
- Management raised full-year guidance, with the addition of For The Record contributing approximately $30 million in annual revenue and modest timing adjustments.
- +7 more takeaways
SunCoke Energy Q1 2026 Earnings Call - Strong Industrial Services Offset Winter Weather Headwinds
SunCoke Energy delivered solid Q1 2026 results, with consolidated Adjusted EBITDA of $56.5 million, despite being weighed down by severe winter weather, a turbine failure at Middletown, and the Haverh...
- Consolidated Q1 2026 Adjusted EBITDA came in at $56.5 million, slightly below the prior year's $59.8 million, driven by severe winter weather, the Haverhill One shutdown, and the Middletown turbine failure.
- Industrial services segment was the standout performer, with Adjusted EBITDA nearly doubling year-over-year to $26.2 million, supported by the addition of Phoenix and strong terminal volume growth.
- Management reaffirmed full-year consolidated Adjusted EBITDA guidance of $230 million to $250 million, citing confidence in making up lost Q1 production in the second half of the year.
- +7 more takeaways
Protolabs Q1 2026 Earnings Call - Record Revenue and Margin Expansion Driven by Aerospace and Defense Demand
Protolabs delivered a record first quarter in 2026, with revenue climbing 10.4% year-over-year to $139.3 million and non-GAAP EPS hitting a five-year high of $0.54. The growth was heavily concentrated...
- Revenue hit a company record of $139.3 million, up 10.4% year-over-year, marking the fourth consecutive quarter of double-digit U.S. growth.
- Non-GAAP EPS reached $0.54, the highest level since Q3 2020, driven by volume growth, 140 basis points of gross margin expansion, and operating leverage.
- CNC machining revenue grew over 20% in the U.S., fueled by sustained demand in aerospace, defense, space exploration, satellites, and robotics.
- +7 more takeaways
Diversified Healthcare Trust Q1 2026 Earnings Call - Operational Turnaround Drives Margin Expansion and Deleveraging
Diversified Healthcare Trust delivered a strong first quarter, driven by aggressive operational improvements and strategic asset reallocation. The company’s active management strategy is paying divide...
- Normalized FFO of $0.14 per share and Adjusted EBITDAre of $74 million both beat analyst consensus estimates.
- Same-property SHOP NOI surged 13.5% year-over-year, reaching $44.3 million, driven by 110 basis points of occupancy growth and 5.9% average monthly rate growth.
- Same-property NOI margin expanded by 160 basis points to 14.9%, aided by a 4.5% average annual rate increase across 70% of the portfolio and improved resident mix.
- +7 more takeaways
Playtika Q1 2026 Earnings Call - Disney Solitaire Drives Record Growth and Strategic Shift
Playtika delivered a strong start to 2026, with Q1 revenue rising 9.7% sequentially and 5.5% year-over-year to $744.7 million, driven by exceptional performance from Disney Solitaire and a record Dire...
- Disney Solitaire scaled faster than any title in Playtika’s 15-year history, generating $123.3 million in Q1 revenue, up 72.1% sequentially, with returns supporting heavy user acquisition investment.
- Q1 revenue reached $744.7 million, up 9.7% sequentially and 5.5% year-over-year, beating expectations and supporting raised full-year guidance.
- Direct-to-Consumer (DTC) revenue hit a record $291.8 million, up 16.7% sequentially and 62.8% year-over-year, pushing the annual run rate close to $1.2 billion.
- +9 more takeaways
The Cigna Group Q1 2026 Earnings Call - Raising Full-Year EPS Outlook to $30.35 Amid Strategic Portfolio Shifts
The Cigna Group delivered a strong first quarter 2026, reporting adjusted EPS of $7.79 and raising its full-year outlook to at least $30.35. The results were driven by robust growth in Evernorth's Spe...
- The Cigna Group raised its full-year 2026 adjusted EPS outlook to at least $30.35, up from previous estimates, citing strong Q1 performance and disciplined execution.
- First-quarter adjusted EPS reached $7.79, with total revenues of $68.5 billion, reflecting 16% year-over-year growth.
- Evernorth Specialty and Care Services pre-tax adjusted earnings surged 20% to $1.1 billion, driven by strong specialty volume growth, increased biosimilar adoption, and contributions from the Shields Health Solutions investment.
- +7 more takeaways
Dutch Bros Q1 2026 Earnings Call - Record Q1 Revenue Growth and Raised Full-Year Guidance
Dutch Bros delivered a formidable Q1 2026, with total revenues surging 31% to $464 million and adjusted EBITDA climbing 26%. The company raised its full-year guidance, projecting total revenues of $2....
- Total revenues surged 31% year-over-year to $464 million, significantly outpacing expectations and driving a 26% increase in adjusted EBITDA.
- Full-year guidance was raised across the board, with total revenues now projected at $2.05-$2.08 billion (25%-27% growth) and adjusted EBITDA expected between $370-$380 million.
- System same-shop sales growth hit an exceptional 8.3% in Q1, with transactions up 5.1% for the seventh consecutive quarter of growth.
- +13 more takeaways
TOMI Environmental Solutions Q1 2026 Earnings Call - Carbonium Core Merger and Pipeline Expansion
TOMI Environmental Solutions reported a strong Q1 2026 with revenue up 5% year-over-year and 67% sequentially, driven by a 139% surge in applicator sales and a growing backlog of $2.2 million. The com...
- Revenue reached $1.6 million in Q1 2026, marking a 5% year-over-year increase and a 67% sequential jump from Q4 2025, signaling strong commercial momentum.
- Applicator sales surged 139% year-over-year, surpassing the entire 2025 total in a single quarter, indicating rapid customer adoption of the iHP technology.
- Backlog expanded to $2.2 million from $1.6 million at year-end 2025, reflecting growing demand for automated integrated systems and recurring service contracts.
- +7 more takeaways
Vaxart Q1 2026 Earnings Call - Sentinel Cohort Data Delayed, Revenue Doubles, Runway Extended to Q2 2027
Vaxart reported a strong first quarter with revenue doubling to $39.2 million, driven by BARDA contracts and Dynavax licensing, resulting in a rare net profit of $5.2 million for a clinical-stage biot...
- Revenue doubled to $39.2 million in Q1 2026, up from $20.9 million in Q1 2025, primarily driven by BARDA contract growth and Dynavax licensing revenue.
- Vaxart posted a net income of $5.2 million ($0.02 per share), a rare profitability milestone for a clinical-stage biotech, aided by reduced R&D and G&A expenses.
- Cash and short-term investments stood at $61 million, with the company extending its cash runway into Q2 2027 through cost-cutting and operational streamlining.
- +12 more takeaways